Background
==========

Glioma is the most frequent primary brain tumor caused by the carcinogenesis of glial cells in the brain. According to the World Health Organization (WHO), gliomas can be differentiated into 4 grades (I--IV). Lower-grade gliomas (LGG) (\[WHO\] grades II and III) are aggressive tumors that occur most commonly in the hemi-cerebrum of adults and include astrocytomas and oligodendrogliomas \[[@b1-medscimonit-25-3716]\]. Due to the aggressive nature of glioma, it is difficult to remove the neoplasm completely by neurosurgical surgery, and the residual tumor is the leading cause of recurrence and disease progression \[[@b2-medscimonit-25-3716]\]. Currently, the main treatments of gliomas are surgery, radiotherapy, chemotherapy, and targeted therapy \[[@b3-medscimonit-25-3716],[@b4-medscimonit-25-3716]\]. Currently, new findings are being made in both basic and translational research, including disordered tumor proliferation signaling pathways, anti-angiogenic therapy, classifying tumor grade, and predicting overall survival \[[@b2-medscimonit-25-3716],[@b5-medscimonit-25-3716]--[@b8-medscimonit-25-3716]\]. To gain further understanding of this heterogeneous disease, we conducted an integrative genome-wide analysis of 511 LGGs from adults, using bioinformatics analysis. By comparing the differentially expressed genes (DEGs) between the primary and recurrent LGG tumor samples, we used bioinformatics methods to screen the hub DEGs and explore the biological processes of DEGs. It is helpful to understand and develop targeted therapeutic drugs for LGG recurrence.

The Cancer Genome Atlas (TCGA) is a catalogue of genetic mutations responsible for cancer (including LGG and glioblastoma), using genome sequencing and bioinformatics \[[@b9-medscimonit-25-3716],[@b10-medscimonit-25-3716]\]. High-throughput genome analysis techniques (including a minimum of 6000 candidate genes and microRNA sequences) from TCGA lead to a superior perception of the genetic basis of this disease. There were 511 LGG patients providing 529 samples (282 males, 228 females, and 1 patient with sex unknown), including 511 primary tumors and 18 recurrent tumors to facilitate information sharing across cancer genomic research. The TCGA database collected mRNA gene expression profiles in LGG and the profiles of LGG; first occurrence and recurrence were compared to identify differentially expressed genes (DEGs) and DEGs were further sorted by gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) analysis. Next, gene co-expression and protein--protein interaction (PPI) networks were investigated by the Search Tool for Recurring Instances of Neighboring Genes (STRING), and module analysis of the DEGs was proceed by Molecular Complex Detection (MCODE) in Cytoscape software. By studying the biological functions and pathways of these DEGs, we can learn more about the pathogenesis, occurrence, and development of LGG and improve the diagnosis and treatment of this disease in the immediate future.

Material and Methods
====================

Data source
-----------

This was a study of publicly available data from The Cancer Genome Atlas (TCGA). RNA sequencing information of LGG was downloaded from TCGA (*<https://cancergenome.nih.gov>*; accessed Nov 4, 2017) \[[@b2-medscimonit-25-3716]\]. A total of 529 LGG samples, including 511 primary tumor samples and 18 recurrent samples, and RNA-sequencing (RNA-seq) datasets were accessed. All these LGG biospecimens were collected from patients diagnosed with diffuse glioma undergoing surgical resection and who had received no prior treatment for their disease (chemotherapy or radiotherapy). All the data were sourced from the TCGA website and used in accordance with the TCGA data access policies and publication guidelines (*<https://cancergenome.nih.gov/publications/publicationguidelines>*). Therefore, additional ethics committee approval was not necessary for the present study.

DEGs
----

We initially made a comparison of the expression of mRNAs between LGG primary tumors and recurrent LGG by differential expression analysis. Then, we screened the differentially expressed mRNAs by edgeR \[[@b11-medscimonit-25-3716],[@b12-medscimonit-25-3716]\] in the R platform. According to DEG scanning, the genes that met a criterion with false discovery rate (FDR) \<0.05 and fold control (FC) ≥2.0 \[[@b13-medscimonit-25-3716]--[@b15-medscimonit-25-3716]\] were identified as DEGs. Next, we plotted the heat map of these DEGs by the *gplots* package in the R platform.

GO enrichment analysis and KEGG pathway analysis of DEGs
--------------------------------------------------------

For the purpose of analyzing the DEGs at the biological function level, GO enrichment analysis and KEGG pathway analysis were performed by using the Database for Annotation, Visualization, and Integration Discovery (DAVID, *<https://david.ncifcrf.gov>*, version 6.8) online tool. Results of GO and KEGG pathway analysis fulfilling a nominal P-value \<0.05 were considered statistically significant \[[@b16-medscimonit-25-3716],[@b17-medscimonit-25-3716]\]. The P-value of the GO enrichment analysis of the DEGs was used for locating the most likely related GO term and confirming gene function in biological models \[[@b18-medscimonit-25-3716],[@b19-medscimonit-25-3716]\]. The KEGG pathway analysis of DEGs can facilitate our understanding of the metabolic pathways altered under experimental conditions, particularly in mechanistic studies.

Protein--protein interaction network and module analysis
--------------------------------------------------------

The online STRING database (*<https://string-db.org>*; accessed September 18, 2017), which was designed to construct a crucial PPI network, evaluates the interactive relationships among DEGs and examines the physical and functional association between oncogenesis-related DEGs \[[@b20-medscimonit-25-3716]\]. Therefore, we assessed the PPI network of the DEGs with STRING. Only co-expressional validated interactions with a combined score \>0.15 were considered statistically significant. Subsequently, we mapped PPI networks of DEGs with Cytoscape software, version 3.5.1, a bioinformatics integration platform, and used MCODE to construct modules of protein--protein interactions with the annotations as follows: scores \>6 and nodes \>7 in Cytoscape. Moreover, GO enrichment and KEGG pathway analysis were performed in the modules to assess for potential oncogenesis-related DEGs, with a P-value \<0.05 considered statistically significant.

Gene set enrichment analysis (GSEA)
-----------------------------------

To further explore the potential molecular mechanisms of LGG recurrence, we also performed a bioinformatics analysis, GSEA, to investigate the differences in pathways and functions between LGG primary and recurrence tumor tissues. The parameter of permutations was set at 1000. The nominal *P*-value of enrichment results cut-off was 0.05, while the false discovery rate (FDR) cut-off was 0.25 \[[@b21-medscimonit-25-3716]--[@b23-medscimonit-25-3716]\].

Statistical analysis
--------------------

In order to combat error in multiple comparisons, we conducted multiple testing with the Benjamini-Hochberg procedure \[[@b13-medscimonit-25-3716]--[@b15-medscimonit-25-3716]\] in edgeR to control FDR. A value of P\<0.05 was considered statistically significant. All statistical analyses were carried out with SPSS version 20.0 (IBM Corporation, Armonk, NY, USA) and R3.3.1.

Results
=======

Identification of DEGs
----------------------

In total, 511 LGG tumor and 18 recurrent specimens were screened for DEGs. The *edgeR* package identified 326 differentially expressed mRNAs, \|log~2~ FC\|≥2, and P-value \<0.05 of which 248 were upregulated and 78 were downregulated and showed a consistent direction of differential expression ([Figure 1](#f1-medscimonit-25-3716){ref-type="fig"}). A heat map of 326 DEGs is shown in [Supplementary Figure 1](#s1-medscimonit-25-3716){ref-type="supplementary-material"}.

GO enrichment analysis and KEGG analysis of DEGs
------------------------------------------------

DAVID was utilized to determine the specific GO terms and KEGG pathways of the DEGs. According to the GO analysis, DEGs were generally enriched in biological process (BP), molecular function (MF), and GO cell components (CC), including neuron differentiation, cell differentiation, negative regulation of neuron differentiation, and cell proliferation in the forebrain ([Figure 2A](#f2-medscimonit-25-3716){ref-type="fig"}). In the KEGG pathway analysis, DEGs were significantly enriched in the wnt signaling pathway, ECM-receptor interaction, signaling pathways regulating pluripotency of stem cells, PI3K-Akt signaling pathway, proteoglycans in cancer, transcriptional misregulation in cancer and Hippo signaling pathway ([Figure 2B](#f2-medscimonit-25-3716){ref-type="fig"}).

Identification of hub genes and MCODE analysis from the PPI network
-------------------------------------------------------------------

STRING analysis was performed to identify the hub genes and hub nodes with the highest degrees of interaction. These included apolipoprotein A2 (APOA2), collagen type III alpha 1 chain (COL3A1), collagen type I alpha 1 chain (COL1A1), tyrosinase (TYR), collagen type I alpha 2 chain (COL1A2), neurotensin (NTS), collagen type V alpha 1 chain (COL5A1), poly(A) polymerase beta (PAPOLB), insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), and anomalous homeobox (ANHX). The Column chart of the mRNA expression level between LGG primary tumor and those recurrent of the top 10 rank hub genes are shown in [Figure 3](#f3-medscimonit-25-3716){ref-type="fig"} and [Table 1](#t1-medscimonit-25-3716){ref-type="table"}. Among them, APOA2 gave rise to 14, the highest node degree. [Figure 4](#f4-medscimonit-25-3716){ref-type="fig"} shows the PPI network of the DEGs. Moreover, the overall number of 326 DEGs were analyzed by the MCODE plugin. We selected the top 3 significant modules and analyzed their functional annotation ([Figure 5A--5C](#f5-medscimonit-25-3716){ref-type="fig"}). GO term enrichment and KEGG pathway analysis revealed that only the genes of module II were mainly associated with ion binding, homeostasis, and regulation of the lipid metabolic process ([Table 2](#t2-medscimonit-25-3716){ref-type="table"}). There were no statistically significant differences between module I and III.

GSEA
----

GSEA analysis between the primary and recurrent tumor tissues using the c2 reference gene set suggest that LGG recurrence is significantly associated with changes in cell cycle, DNA replication, apoptosis by CDKN1A via TP53, DNA repair, regulation of apoptosis, neuronal differentiation, and Wnt signaling pathway genes ([Figure 6A--6P](#f6-medscimonit-25-3716){ref-type="fig"}). However, no results reached the statistical significance in the GSEA analysis using the c5 reference gene set.

Discussion
==========

Numerous studies have shown that genetic status is more likely to reflect disease subtypes than is histology \[[@b2-medscimonit-25-3716],[@b5-medscimonit-25-3716],[@b6-medscimonit-25-3716]\]. An integrated, multiplatform genomics system was utilized to investigate the biological basics of adult LGG. The present study compared LGG tumor and 18 recurrent specimens to identify DEGs and then used gene set enrichment analysis (GSEA) to investigate and interpret differences in gene expression. The *edgeR* package identified 326 differentially expressed mRNAs, of which 248 were upregulated and 78 were downregulated, showing a consistent direction of differential expression. We then performed GO enrichment and KEGG analysis to consider the interactions of these DEGs. We identified a number of key genes that may provide new insight into LGG therapies.

GO enrichment analysis revealed that the DEGs were mostly involved in cell differentiation, positive regulation of cell proliferation, neuron differentiation, positive regulation of epithelial cell proliferation, and cell-cell signaling. CD109 is a critical regulator of the progression of LGG. It has been reported that CD109-positive brain tumor stem cells exert a proliferative effect on cell differentiation of glioma to promote their survival and resistance to conventional therapies \[[@b24-medscimonit-25-3716]\]. Additionally, ciliary neurotrophic factor receptor alpha subunit (CNTFRalpha) and CNTF have considerable roles in neuronal survival, neuroglial differentiation and glioma growth. Hypomethylation leading to CNTFRalpha upregulation has been proposed to be involved in glioma growth regulation \[[@b25-medscimonit-25-3716]\].

In addition, the results of the KEGG analysis mainly included DEGs involved in the Wnt signaling pathway, PI3K-Akt signaling pathway, ECM-receptor interaction, and neuroactive ligand-receptor interactions. Wnt signaling pathways manage proliferation, motility, and survival in many human cell types. Indeed, the dickkopf 1 (DKK1) gene codes for a secreted Wnt inhibitory factor and functions as a pro-apoptotic factor in glioma cells \[[@b26-medscimonit-25-3716]\]. By means of variable activation of the Wnt/beta-catenin signaling pathway, the (pro)renin receptor (PRR) plays a crucial role in development of glioma \[[@b27-medscimonit-25-3716]\], with poor prognostic implications for the final outcome of brain glioma via SFRP1 inhibition and Wnt activation reported to contribute to the infiltrative glioma phenotype at early stages of disease progression \[[@b28-medscimonit-25-3716]\]. Radio-proteomics analysis has shown that the phenotypic consequences of molecular aberrations in LGGs are correlated with expression of PI3K/Akt signaling pathways \[[@b29-medscimonit-25-3716]\]. Moreover, the tumorigenesis of pleomorphic glioblastoma may increase with the enhancement aggregation of affected genes on specific molecular pathways (e.g., focal adhesion or ECM-receptor interaction) \[[@b30-medscimonit-25-3716]\]. An integrated analysis of mutated genes from India identified GBMs with defective neuroactive ligand-receptor interaction pathways were associated with a significantly worse prognosis \[[@b31-medscimonit-25-3716]\]. In addition, the findings from GSEA also verify the KEGG enrichment results showing that, compared to LGG primary, recurrence tumor tissues were significantly enriched in the Wnt signaling pathway. Other enrichment results of GSEA also suggested that LGG recurrence may involve the basic status of cells, such as cell cycle, differentiation, DNA repair, and regulation of apoptosis. Therefore, we conclude that the recurrent mechanism of LGG involves the basic state of neurons, such as neuronal differentiation, cell cycle, DNA repair, and apoptosis.

We used the STRING online tool and Cytoscape software to construct the PPI network of DEGs. The highest-grade interaction genes were APOA2, COL3A1, COL1A1, TYR, COL1A2, NTS, COL5A1, PAPOLB, IGF2BP1, and ANHX. *APOA2* encodes apolipoprotein (apo-) A-II, which is the second most abundant protein of high-density lipoprotein particles. Apolipoprotein A-II deficiency or hypercholesterolemia is caused by this gene defect. Moreover, disruption to the blood-brain barrier in pediatric brain tumor patients is likely to be the main reason for high overexpression of apolipoprotein A-II in the cerebrospinal fluid (CSF) \[[@b32-medscimonit-25-3716]\]. Furthermore, some studies suggest that ApoA-II may have drug delivery potential and utility as a marker in identifying indolent disease, such as the pathogenesis of liver cancer \[[@b33-medscimonit-25-3716]--[@b35-medscimonit-25-3716]\].

The second hub gene, *COL3A1,* encodes collagen alpha-1 (III) chain, a protein which is a precursor to collagen III, continually combined with type I collagen. As a member of the collagen family, collagen alpha-1 (III) (COL3A1) is an important protein in the development and progression of several tumors, as it induces profound angiogenic responses in the host brain microvasculature that promote tumor growth \[[@b36-medscimonit-25-3716],[@b37-medscimonit-25-3716]\]. Moreover, some studies determined that COL3A1 expression was upregulated in glioma and was directly correlated with the tumor grade \[[@b36-medscimonit-25-3716],[@b38-medscimonit-25-3716]\]. As COL3A1 localizes to the extracellular matrix and was selectively expressed by the microvasculature, it may be a novel regulator of glioblastoma cell behavior and may be a suitable biomarker for diagnostic use or as a novel target for gene therapies against glioma \[[@b37-medscimonit-25-3716],[@b38-medscimonit-25-3716]\].

COL1A1 encodes the major component of type I collagen, the fibrillar collagen that exists in masses of connective tissues. In both LGG and glioblastoma, overexpression of COL1A1 was found to be directly correlated with the tumor grade \[[@b39-medscimonit-25-3716]\]. The upregulated expression of collagen 2 in glioma is accompanied by upregulation of COL1A1. The effect of mesenchymal-associated genes on cell invasion and gliomasphere initiation were identified *in vitro,* by silencing of COL1A1, in which the gene has the potential for stratifying patients with glioma into subgroups for diagnosis of recurrence risk, as well as prognostic and therapeutic evolution \[[@b37-medscimonit-25-3716],[@b39-medscimonit-25-3716],[@b40-medscimonit-25-3716]\].

Human tyrosinase is a single-membrane-spanning transmembrane protein, encoded by the TYR gene. Complete tumor resection can improve progression-free survival and overall survival. The ability to differentiate tumor cells during surgery can increase the success rate of tumor resection, thereby increasing the survival time of patients. Fluorescence-labeled tumor-specific antibodies (second tyrosinase-related protein) can accurately and specifically bind and identify tumor cells *in vivo*. The development of such brain tumor markers will contribute to the application of intraoperative fluorescence microscopy to increase the resection range of various intracranial tumors \[[@b41-medscimonit-25-3716]\]. Some studies \[[@b42-medscimonit-25-3716]\] have found that the tyrosinase promoter was significantly overexpressed in primary glioma samples, and tyrosinase expression correlated with the grade of the tumor. The role of the intracranial microenvironment in sculpting a location-specific profile of tumor antigen expression is very important, and clinical application of targeting novel anti-glioma therapies with checkpoint inhibition for aggressive brain tumors may be feasible \[[@b43-medscimonit-25-3716],[@b44-medscimonit-25-3716]\].

The COL1A2 gene encodes one of the chains for type I collagen. COL1A2 plays an important role in medulloblastoma tumorigenesis \[[@b45-medscimonit-25-3716]\]. Additionally, COL1A2 expression was differentiated in infant medulloblastomas of the desmoplastic histopathological subtype, suggesting that this distinct molecular pathogenesis may be the basis for these tumors and their relatively good prognosis. It is a powerful demonstration that the methylation status of specific genes may be relevant to the biological subclassification of medulloblastoma \[[@b45-medscimonit-25-3716]--[@b47-medscimonit-25-3716]\].

The NTS gene encodes a common precursor for 2 peptides: neuromedin N and neurotensin. Neurotensin is a secreted tridecapeptide, diffusely distributed throughout the central nervous system, and may serve as a neurotransmitter or a neuromodulator. Moreover, neurotensin (NTS) and its primary receptor, NTSR1, are implicated in cancer progression. Abnormal gene expression of NTS/NTSR1 results in the proliferation of glioblastoma cells. The expression level of NTS and NTSR1 was positively correlated with pathological grading of glioma. In keeping with this, unfavorable prognosis in glioma patients was associated with high expression levels of NTS and NTSR1 \[[@b48-medscimonit-25-3716],[@b49-medscimonit-25-3716]\]. Furthermore, the suppression of the NTSR1 function or the upregulation of miR-29b-1 and miR-129-3p expression decreased glioma cell proliferation, which suggests the NTS/NTSR1/c-Myc/miRNA axis may be a feasible therapeutic target for glioblastoma therapy \[[@b50-medscimonit-25-3716]\].

An alpha chain for one of the low-abundance fibrillar collagens was encoded by COL5A1 gene. It has been proven that fibrin collagen exists widely in GBMs and mediates the invasion of tumor cells through a collagen-containing matrix \[[@b51-medscimonit-25-3716]\]. Collagen scaffolds have been shown to be a major factor associated with angiogenesis, metastasis, and rapid tumor growth in solid gliomas \[[@b52-medscimonit-25-3716]\].

PAPOLB gene is a protein-coding gene for poly(A) polymerase beta. Some studies \[[@b53-medscimonit-25-3716],[@b54-medscimonit-25-3716]\] suggest that PAPOLB regulates germ cell morphogenesis by modulating specific transcription factors at posttranscriptional and posttranslational levels. Our study found that this gene is associated with the development of glioma, but this requires more research to clarify.

IGF2BP1 gene encodes a member of the insulin-like growth factor 2 mRNA-binding protein family. It regulates some genes (including insulin-like growth factor 2, -actin and-transduction proteins) translation by binding to their mRNA. Some studies \[[@b55-medscimonit-25-3716],[@b56-medscimonit-25-3716]\] found that IGFBP subtype has become a biomarker for diagnosis and prognosis of astrocytomas. IGF2BP3 was identified as a GBM-specific proliferative and pre-invasive marker that activates the oncogene PI3K and MAPK pathways through the action of IGF-2 \[[@b57-medscimonit-25-3716]\].

The ANHX gene is a protein-coding gene for anomalous homeobox. Through the identification of homologous domains, homologous proteins regulate the expression of target genes and guide the formation of many body structures during early embryonic development \[[@b58-medscimonit-25-3716]\]. Over the past 2 decades, many studies have been published on how homologous proteins bind to DNA and increase their specificity by interacting with other proteins to regulate cell and tissue-specific gene expression \[[@b59-medscimonit-25-3716]\]. The present study has demonstrated that the ANHX gene potentially acts as novel biomarker and therapeutic target for clinical assay development.

In the present study, a major limitation is that the results generated were obtained from a unitary cohort from TCGA, and the samples size of LGG recurrent tumor tissues is small. Since this is a bioinformatics study of data mining, the number of samples, differential expression genes, and hub genes screening methods can affect the reproducibility of the results. Therefore, our findings still need to be verified in another cohort in future studies. However, despite this limitation, we identified a large number of DEGs between LGG primary and recurrent tumor tissues, and investigated the key genes and potential molecular mechanism by using multiple bioinformatics analysis methods, including GSEA. These findings may help to advance the understanding of LGG recurrence, and may have potential applications of value in LGG recurrence detection or targeted therapy.

Conclusions
===========

In this study, 326 differentially-expressed genes associated with LGG recurrence were integrated analyzed and hub 10 genes were identified by bioinformatics. We also explored the potential mechanisms related to LGG relapse through functional enrichment assessment and GSEA methods. The study revealed that LGG relapse influences the basic functional status of cells, such as cell cycle, differentiation, DNA repair, and regulation of apoptosis. However, the findings of our study still require further verification in other cohorts.

Supplementary Figure
====================

###### 

Heat map of the 326 DEGs. Red: upregulation; green: downregulation. DEGs -- differentially-expressed genes.
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![Volcano plot of the DEGs between LGG primary and recurrence tumor tissues. Red: upregulation; green: downregulation; black: non-differentially-expressed genes. DEGs -- differentially expressed genes; LGG -- lower-grade glioma](medscimonit-25-3716-g001){#f1-medscimonit-25-3716}

![Functional assessment for DEGs between LGG primary and recurrence tumor tissues. (**A**) GO term enrichment results; (**B**) KEGG enrichment results. DEGs -- differentially-expressed genes; LGG -- lower-grade glioma; GO -- gene ontology; KEGG -- Kyoto Encyclopedia of Genes and Genomes](medscimonit-25-3716-g002){#f2-medscimonit-25-3716}

![Column chart of the top 10 rank hub genes mRNA expression level between LGG primary and recurrence tumor tissues. APOA2 -- apolipoprotein A2; COL3A1 -- collagen type III alpha 1 chain; COL1A1 -- collagen type I alpha 1 chain; TYR -- tyrosinase; COL1A2 -- collagen type I alpha 2 chain; NTS -- neurotensin; COL5A1 -- collagen type V alpha 1 chain; PAPOLB -- poly(A) polymerase beta; IGF2BP1 -- insulin-like growth factor 2 mRNA-binding protein 1; ANHX -- anomalous homeobox; LGG -- lower-grade glioma](medscimonit-25-3716-g003){#f3-medscimonit-25-3716}

![Protein--protein interaction networks of DEGs between LGG primary and recurrence tumor tissues. Green text: DEGs; Purple text: 10 hub genes of DEGs in the PPI networks. DEGs -- differentially-expressed genes; LGG -- lower-grade glioma; PPI -- protein--protein interaction.](medscimonit-25-3716-g004){#f4-medscimonit-25-3716}

![Top 3 modules from the PPI networks. (**A**) Module 1; (**B**) module 2; (**C**) module 3. PPI -- protein--protein interaction](medscimonit-25-3716-g005){#f5-medscimonit-25-3716}

![GSEA comparison of c2 reference gene set (**A--P**) between LGG primary and recurrence tumor tissues. ES -- enrichment score; FDR -- false discovery rate; GSEA -- gene set enrichment analysis.](medscimonit-25-3716-g006){#f6-medscimonit-25-3716}

###### 

Fold change list of the top 10 hub differentially expressed genes between LGG primary and recurrence tumor tissues.

  ID        Log2FC         P value       FDR           Change
  --------- -------------- ------------- ------------- -----------------
  NTS       −3.998653652   0.004369524   0.020863775   Down-regulation
  APOA2     −3.357158871   0.009228557   0.036982495   Down-regulation
  PAPOLB    2.01120252     1.43E-12      9.93E-11      Up-regulation
  TYR       2.058023707    0.000339247   0.002609601   Up-regulation
  IGF2BP1   2.558024781    1.10E-10      5.33E-09      Up-regulation
  COL3A1    2.81332624     4.01E-13      3.07E-11      Up-regulation
  COL1A1    2.816660818    1.61E-13      1.31E-11      Up-regulation
  COL5A1    3.047914457    8.18E-24      1.51E-21      Up-regulation
  COL1A2    3.249927208    3.21E-32      8.57E-30      Up-regulation
  ANHX      4.581419911    5.44E-25      1.04E-22      Up-regulation

FC -- fold change; APOA2 -- apolipoprotein A2; COL3A1 -- collagen type III alpha 1 chain; COL1A1 -- collagen type I alpha 1 chain; TYR -- tyrosinase; COL1A2 -- collagen type I alpha 2 chain; NTS -- neurotensin; COL5A1 -- collagen type V alpha 1 chain; PAPOLB -- poly(A) polymerase beta; IGF2BP1 -- insulin like growth factor 2 mRNA binding protein 1; ANHX -- anomalous homeobox; LGG -- lower grade glioma; FDR -- false discovery rate.

###### 

The result of the top module II using GO term enrichment and KEGG pathway analysis.

  ID           Term                                                         P value       Genes
  ------------ ------------------------------------------------------------ ------------- ----------------------------------------------------------
  **GO**                                                                                  
  GO:0030574   Collagen catabolic process                                   1.68E-14      COL3A1, COL1A2, COL6A2, COL15A1, COL1A1, ADAMTS2, COL5A1
  GO:0005581   Collagen trimer                                              6.12E-11      COL3A1, COL1A2, COL6A2, COL15A1, COL1A1, COL5A1
  GO:0030199   Collagen fibril organization                                 8.65E-10      COL3A1, COL1A2, COL1A1, ADAMTS2, COL5A1
  GO:0005788   Endoplasmic reticulum lumen                                  2.54E-09      COL3A1, COL1A2, COL6A2, COL15A1, COL1A1, COL5A1
  GO:0048407   Platelet-derived growth factor binding                       7.19E-09      COL3A1, COL1A2, COL1A1, COL5A1
  GO:0005201   Extracellular matrix structural constituent                  7.86E-09      COL3A1, COL1A2, COL15A1, COL1A1, COL5A1
  GO:0005578   Proteinaceous extracellular matrix                           1.36E-08      CD248, COL1A2, COL6A2, COL15A1, ADAMTS2, COL5A1
  GO:0031012   Extracellular matrix                                         2.24E-08      COL3A1, COL1A2, COL6A2, COL15A1, COL1A1, COL5A1
  GO:0030198   Extracellular matrix organization                            6.13E-07      COL3A1, COL1A2, COL6A2, COL1A1, COL5A1
  GO:0005576   Extracellular region                                         3.05E-06      COL3A1, COL1A2, COL6A2, COL15A1, COL1A1, ADAMTS2, COL5A1
  GO:0070208   Protein heterotrimerization                                  1.35E-05      COL1A2, COL6A2, COL1A1
  GO:0043588   Skin development                                             8.30E-05      COL3A1, ADAMTS2, COL5A1
  GO:0001568   Blood vessel development                                     1.04E-04      COL1A2, COL1A1, COL5A1
  GO:0071230   Cellular response to amino acid stimulus                     1.60E-04      COL3A1, COL1A2, COL1A1
  GO:0007155   Cell adhesion                                                6.54E-04      COL6A2, COL15A1, COL1A1, COL5A1
  GO:0005584   Collagen type i trimer                                       7.68E-04      COL1A2, COL1A1
  GO:0005615   Extracellular space                                          8.67E-04      COL3A1, COL1A2, COL6A2, COL15A1, COL1A1
  GO:0030168   Platelet activation                                          9.55E-04      COL3A1, COL1A2, COL1A1
  GO:0001501   Skeletal system development                                  0.001350963   COL3A1, COL1A2, COL1A1
  GO:0050776   Regulation of immune response                                0.002265849   COL3A1, COL1A2, COL1A1
  GO:0032964   Collagen biosynthetic process                                0.002498958   COL1A1, COL5A1
  GO:0043589   Skin morphogenesis                                           0.003746428   COL1A2, COL1A1
  GO:0043206   Extracellular fibril organization                            0.00499256    COL3A1, COL5A1
  GO:0070062   Extracellular exosome                                        0.013361493   CD248, COL1A2, COL6A2, COL15A1, COL5A1
  GO:0046332   SMAD binding                                                 0.017698138   COL3A1, COL1A2
  GO:0007179   Transforming growth factor beta receptor signaling pathway   0.03773359    COL3A1, COL1A2
  GO:0005178   Integrin binding                                             0.042743441   COL3A1, COL5A1
  GO:0046872   Metal ion binding                                            0.043964665   COL3A1, COL1A2, COL1A1, COL5A1
  GO:0050900   Leukocyte migration                                          0.04977108    COL1A2, COL1A1
  **KEGG**                                                                                
  hsa04974     Protein digestion and absorption                             2.99E-10      COL3A1, COL1A2, COL6A2, COL15A1, COL1A1, COL5A1
  hsa04512     ECM-receptor interaction                                     1.16E-07      COL3A1, COL1A2, COL6A2, COL1A1, COL5A1
  hsa04510     Focal adhesion                                               3.75E-06      COL3A1, COL1A2, COL6A2, COL1A1, COL5A1
  hsa04151     PI3K-Akt signaling pathway                                   2.94E-05      COL3A1, COL1A2, COL6A2, COL1A1, COL5A1
  hsa05146     Amoebiasis                                                   3.43E-05      COL3A1, COL1A2, COL1A1, COL5A1
  hsa04611     Platelet activation                                          6.33E-05      COL3A1, COL1A2, COL1A1, COL5A1

GO -- gene ontology; KEGG -- Kyoto Encyclopedia of Genes and Genomes.
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